Efavirenz in an obese HIV-infected patient – a report and an in vitro–in vivo extrapolation model indicate risk of underdosing
Détails
ID Serval
serval:BIB_2B532405FD6A
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Etude de cas (case report): rapporte une observation et la commente brièvement.
Collection
Publications
Institution
Titre
Efavirenz in an obese HIV-infected patient – a report and an in vitro–in vivo extrapolation model indicate risk of underdosing
Périodique
Antiviral therapy
ISSN
2040-2058 (Electronic))
ISSN-L
1359-6535
Statut éditorial
Publié
Date de publication
2012
Peer-reviewed
Oui
Volume
17
Numéro
7
Pages
1381-1384
Langue
anglais
Notes
Publication types: Case Reports ; Journal Article
Publication Status: ppublish
Publication Status: ppublish
Résumé
Here, we report suboptimal efavirenz exposure in an obese patient treated with the standard 600 mg dose. Tripling the dose allowed attainment of therapeutic efavirenz concentrations. We developed an in vitro-in vivo extrapolation model to quantify dose requirements in obese individuals. Obesity represents a risk factor for antiretroviral therapy underdosing.
Mots-clé
Benzoxazines/administration & dosage, Benzoxazines/pharmacokinetics, Body Mass Index, Computer Simulation, Drug Dosage Calculations, Drug Monitoring/methods, HIV/pathogenicity, HIV Infections/drug therapy, HIV Infections/pathology, HIV Infections/virology, Humans, Male, Middle Aged, Obesity/pathology, RNA, Viral/blood, Reverse Transcriptase Inhibitors/administration & dosage, Reverse Transcriptase Inhibitors/pharmacokinetics, Risk Factors, Viral Load
Pubmed
Web of science
Création de la notice
13/12/2012 19:50
Dernière modification de la notice
25/08/2023 19:44
Données d'usage
